BusinessWeek - Nigel Beeley is a biopharma veteran. He spent 25 years in research at such biotechnology companies as Amylin Pharmaceuticals (AMLN), Arena Pharmaceuticals (ARNA), and Senomyx (SNMX). He had a hand in creating cancer and metabolic disease drugs Mylotarg, Symlin, Byetta, and Lorcaserin. But when he decided to start his own company based on pharmaceutical discoveries, he made a switch to a field many might find surprising: emerging alternative energy.
